Altimmune's Alcohol Use Disorder Drug Reduces Heavy Drinking in Mid-Stage Trial

Altimmune announced positive results from a mid-stage clinical trial of its experimental drug for alcohol use disorder. The company reported that the drug statistically significantly reduced heavy drinking behavior in the trial. These results offer the potential for a new treatment option for alcohol dependence. The trial monitored participants' alcohol consumption habits over a specific period and observed that the drug significantly reduced heavy drinking days compared to a placebo. Altimmune stated that these data provide strong evidence of the drug's efficacy and lay the groundwork for advanced-stage studies. The company noted that current treatment options for alcohol use disorder are limited and emphasized that this drug could offer new hope for patients. Altimmune plans to share the trial results with regulatory authorities and take the necessary steps for the next phase. This is not investment advice.